Please assess the completion status of the following clinical trial:

Trial Title: Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* Peripheral capillary oxygen saturation (SpO2) ≥ 95% on room air at screening~* Age ≥18 years~Exclusion Criteria:~* Hospitalized or impending hospitalization at the time of screening~* Symptoms of cough, fever or shortness of breath within 72 hours~* Prior or current treatment with other experimental or approved agents targeting SARS-CoV-2 or SARS-CoV-1~* Positive pregnancy test~* Active autoimmune disease or sarcoidosis (with the exception of controlled thyroid disease)~* Active decompensated liver disease (ascites, encephalopathy)~* Active congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon lambda alfa-1a (Type: EXPERIMENTAL): peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2

Based on this trial design, predict the completion outcome and termination type (if applicable).